1018978-91-0

Basic information

• Product Name: (S)-7-fluorochroman-4-amine
• Synonyms: (S)-7-fluorochroman-4-amine
• CAS NO: 1018978-91-0
• Molecular Formula: C9H10FNO
• Molecular Weight: 167.1802032
• Mol File: 1018978-91-0.mol

Chemical Properties

• Boiling Point: 232.27 °C at 760 mmHg
• Flash Point: 94.274 °C
• Appearance: /
• Density: 1.202 g/cm³
• Storage Temp.: 2-8°C
• PKA: 8.68±0.20(Predicted)
• CAS DataBase Reference: (S)-7-fluorochroman-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-7-fluorochroman-4-amine(1018978-91-0)
• EPA Substance Registry System: (S)-7-fluorochroman-4-amine(1018978-91-0)

Safety Data

• Hazardous Substances Data: 1018978-91-0(Hazardous Substances Data)

Usage

Uses

Given the provided materials, there are no specific applications listed for (S)-7-Fluorochroman-4-amine. (S)-7-Fluorochroman-4-amine is described as having potential pharmacological properties and biological activities, but without concrete examples or detailed studies, it is not possible to list its uses in various industries or as an application type for a specific reason. Further research is necessary to explore and confirm its practical applications in fields such as pharmaceuticals, chemical research, or material science.

Upstream product

• 113209-68-0 3,4-dihydro-7-fluoro-2H-1-benzopyran-4-one 

Downstream Products

• 1610343-24-2 1-(1',4-dimethyl-1-phenyl-1H,1'H-[3,4'-bipyrazol]-5-yl)-3-(7-fluorochroman-4-yl)urea 

Relevant articles and documents

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III: